Cegedim SA (LON:0DYQ)
London · Delayed Price · Currency is GBP · Price in EUR 13.15
+1.25 (10.50%)
Feb 12, 2026, 8:22 AM GMT
Cegedim Revenue
Cegedim had revenue of 322.50M EUR in the half year ending June 30, 2025, with 7.14% growth. This brings the company's revenue in the last twelve months to 658.00M, up 3.79% year-over-year. In the year 2024, Cegedim had annual revenue of 654.50M with 6.25% growth.
Revenue (ttm)
658.00M EUR
Revenue Growth
+3.79%
P/S Ratio
0.27
Revenue / Employee
99.62K EUR
Employees
6,605
Market Cap
153.52M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 654.50M | 38.50M | 6.25% |
| Dec 31, 2023 | 616.00M | 60.79M | 10.95% |
| Dec 31, 2022 | 555.21M | 30.50M | 5.81% |
| Dec 31, 2021 | 524.71M | 27.77M | 5.59% |
| Dec 31, 2020 | 496.94M | -6.81M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Optima Health | 113.75M |
| Animalcare Group | 81.07M |
| EKF Diagnostics Holdings | 50.22M |
| Tristel | 46.46M |
Cegedim News
- 5 months ago - Cegedim's profitability improving as expected in H1 2025 - Benzinga